Table 5. Stratified Results of Tumor Response and Survival 2 Year and Analysis of Median Survival.
| Subgroup | Numbers at Risk | CR (%) | PD (%) | Cumulative PFS Rate (%) | Median PFS (Months) | Cumulative LTP Free Survival Rate (%) | Median LTP Free Survival (Months) | Cumulative OS Rate (%) | |
|---|---|---|---|---|---|---|---|---|---|
| Child-Pugh score A5 vs. A6–B7 | |||||||||
| A5 | 73 | 18 (24.7) | 55 (75.3) | 27.2 | 12.0 | 35.8 | 16.8 | 84.7 | |
| A6 or B7 | 34 | 3 (8.8) | 31 (91.2) | 11.2 | 6.4 | 11.9 | 7.0 | 67.9 | |
| p value | 0.055 | 0.055 | 0.004 | 0.001 | 0.015 | ||||
| Tumor multiplicity | |||||||||
| Single | 60 | 20 (33.3) | 40 (66.7) | 35.1 | 16.8 | 37.8 | 16.9 | 84.7 | |
| Multiple | 47 | 1 (2.1) | 46 (97.9) | 3.3 | 6.8 | 15.2 | 7.8 | 73.7 | |
| p value | < 0.001 | < 0.001 | < 0.001 | 0.003 | 0.120 | ||||
| Single tumor, cm | |||||||||
| < 2 | 16 | 6 (37.5) | 10 (62.5) | 40.5 | 9.4 | 40.5 | 11.6 | 81.3 | |
| 2–5 | 35 | 12 (34.3) | 23 (65.7) | 33.7 | 16.8 | 38.0 | 16.9 | 87.9 | |
| > 5 | 9 | 2 (22.2) | 7 (77.8) | 30.6 | 8.4 | 33.7 | 18.3 | 78.6 | |
| p value | 0.726 | 0.726 | 0.636 | 0.714 | 0.467 | ||||
| Multiple tumors | |||||||||
| Within Milan | 24 | 1 (4.2) | 23 (95.8) | 5.7 | 9.3 | 24.0 | 10.8 | 75.8 | |
| Beyond Milan | 23 | 0 (0) | 23 (100) | 0 | 4.2 | 0 | 4.8 | 71.2 | |
| p value | 1.000 | 1.000 | < 0.001 | 0.003 | 0.869 | ||||
| Tumor distribution | |||||||||
| Unilobar | 77 | 19 (24.7) | 58 (75.3) | 28.1 | 10.6 | 30.8 | 12.3 | 83.2 | |
| Bilobar | 30 | 2 (6.7) | 28 (93.3) | 5.2 | 7.0 | 20.6 | 8.4 | 70.6 | |
| p value | 0.035 | 0.035 | 0.010 | 0.296 | 0.105 | ||||
| BCLC stage* | |||||||||
| 0 | 10 | 4 (40.0) | 6 (60.0) | 40.4 | 23.1 | 40.4 | 23.1 | 100 | |
| A | 55 | 13 (23.6) | 42 (76.4) | 26.5 | 13.1 | 36.5 | 14.8 | 84.2 | |
| B | 16 | 0 (0) | 16 (100) | 0 | 4.2 | 0 | 5.8 | 67.4 | |
| C | 26 | 4 (15.4) | 22 (84.6) | 15.8 | 7.3 | 15.9 | 8.7 | 71.2 | |
| p value | 0.062† | 0.062† | < 0.001 | 0.001 | 0.123 | ||||
| Okuda stage | |||||||||
| I | 95 | 21 (22.1) | 74 (77.9) | 24.8 | 10.6 | 32.1 | 13.1 | 81.8 | |
| II | 12 | 0 (0) | 12 (100) | 0 | 8.0 | 0 | 8.0 | 61.4 | |
| p value | 0.118‡ | 0.118‡ | 0.053 | 0.006 | 0.130 | ||||
| Modified UICC stage | |||||||||
| I | 16 | 6 (37.5) | 10 (62.5) | 40.5 | 9.4 | 40.5 | 11.6 | 81.3 | |
| II | 52 | 15 (28.8) | 37 (71.2) | 32.3 | 14.8 | 34.1 | 14.8 | 83.7 | |
| III | 39 | 0 (0) | 39 (100) | 0 | 6.0 | 14.3 | 7.0 | 73.9 | |
| p value | < 0.001 | < 0.001 | < 0.001 | 0.024 | 0.444 | ||||
| Alpha fetoprotein level, ng/mL | |||||||||
| ≤ 20 | 53 | 14 (26.4) | 39 (73.6) | 31.9 | 10.8 | 34.6 | 11.6 | 82.6 | |
| > 20, ≤ 400 | 36 | 5 (13.9) | 31 (86.1) | 15.0 | 9.0 | 26.7 | 14.8 | 82.0 | |
| > 400 | 18 | 2 (11.1) | 16 (88.9) | 9.7 | 6.8 | 11.4 | 7.1 | 66.0 | |
| p value | 0.209 | 0.209 | 0.185 | 0.324 | 0.266 | ||||
*BCLC stage A included all the patients with single tumor regardless of its size, †Chi-squared test for trend, ‡Fisher's exact test. BCLC = Barcelona Clinic Liver Cancer, CR = complete response, LTP = local tumor progression, PD = progressive disease, PFS = progression-free survival, UICC = Union for International Cancer Control